Skip to content

Evaluation of alprazolam effect on tinnitus in the patients of Rasht Amiralmomenin Hospital

Evaluation of alprazolam effect on tinnitus

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT138709121483N1
Enrollment
30
Registered
2009-01-01
Start date
2006-11-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinnitus. Tinnitus

Interventions

Chlordiazepoxide 5 mg bid for 14 days before initiating the main interventions.
Intervention 1: Alprazolam 0.5 mg daily for 2 weeks, then 0.5 mg bid for 2 weeks, then 0.5 mg tid for 4 weeks, then 0.5 mg bid for 3 days, then 0.5 mg daily for 3 days. Intervention 2: Chlorpheniramin
Treatment - Drugs
Alprazolam 0.5 mg daily for 2 weeks, then 0.5 mg bid for 2 weeks, then 0.5 mg tid for 4 weeks, then 0.5 mg bid for 3 days, then 0.5 mg daily for 3 days
Chlorpheniramine 0.5 mg daily for 2 weeks, then 0.5 mg bid for 2 weeks, then 0.5 mg tid for 4 weeks, then 0.5 mg bid for 3 days, then 0.5 mg daily for 3 days

Sponsors

Guilan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
21 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Duration of tinnitus more than 1 year 2- Non pulsative tinnitus Exclusion criteria:1- pulsative tinnitus 2- Meniere's disease 3- Vestibular Schwannoma 4-Otosclerosis 5-Hearing aid users 6- Temporal lobe tumor 7-Depression 8-Anxiety 9- Unable to tolerate minimal effective dose (0.5 mg Alprazolam bid)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Tinnitus severity. Timepoint: at -3, 0, 8, 10, 18th week. Method of measurement: Tinnitus Handicap Inventory questionnaire.;Tinnitus test. Timepoint: at -3, 0, 8, 10, 18th week. Method of measurement: loudness matching.;Severity of Tinnitus. Timepoint: at -3, 0, 8, 10, 18th week. Method of measurement: Visual Analog Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Sapideh Hajforosh

Guilan University of Medical Sciences

+98 13 1223 8307

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026